SYRE
Spyre Therapeutics Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$4.08B
P/E Ratio
—
EPS
$-1.98
Beta
2.94
52W High
$54.33
52W Low
$11.50
50-Day MA
$39.94
200-Day MA
$26.42
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Spyre Therapeutics Inc.
Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. The company is headquartered in Waltham, Massachusetts.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-171.65M |
| EBITDA | $-207.82M |
| Operating Margin | 0.00% |
| Return on Equity | -25.20% |
| Return on Assets | -19.80% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $7.16 |
| Price-to-Book | 6.67 |
| Price-to-Sales (TTM) | 650.22 |
| EV/Revenue | 1964.91 |
| EV/EBITDA | -7.96 |
| Quarterly Earnings Growth (YoY) | -99.70% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $78.54M |
| Float | $64.39M |
| % Insiders | 6.62% |
| % Institutions | 104.83% |
Historical Volatility
HV 10-Day
76.42%
HV 20-Day
69.41%
HV 30-Day
61.22%
HV 60-Day
61.41%
HV Rank
39.7%
Volatility is currently expanding
Analyst Ratings
Consensus ($64.36 target)
15
BuyData last updated: 4/9/2026